Page last updated: 2024-09-05

n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and quinazolines

n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide has been researched along with quinazolines in 1 studies

*Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. [MeSH]

*Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. [MeSH]

Compound Research Comparison

Studies
(n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide)
Trials
(n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide)
Recent Studies (post-2010)
(n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide)
Studies
(quinazolines)
Trials
(quinazolines)
Recent Studies (post-2010) (quinazolines)
1851319,2352,4178,835

Protein Interaction Comparison

ProteinTaxonomyn-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide (IC50)quinazolines (IC50)
Epidermal growth factor receptorHomo sapiens (human)0.027

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Asada, M; Funahashi, Y; Ito, K; Semba, T; Uenaka, T; Wakabayashi, T1

Other Studies

1 other study(ies) available for n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and quinazolines

ArticleYear
Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.
    Cancer science, 2014, Volume: 105, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays

2014